Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-01 |
2024-03 |
-0.11 |
0.73 |
0.84 |
763.64% |
2024-02-28 |
2023-12 |
-0.03 |
0.47 |
0.5 |
1666.67% |
2023-11-01 |
2023-09 |
-1.66 |
-0.46 |
1.2 |
72.29% |
2023-08-02 |
2023-06 |
-1.89 |
-0.27 |
1.62 |
85.71% |
2023-05-02 |
2023-03 |
-1.46 |
-0.97 |
0.49 |
33.56% |
2023-02-28 |
2022-12 |
-1.28 |
-1.24 |
0.04 |
3.13% |
Date |
Firm |
Action |
From |
To |
2023-09-25 |
Mizuho |
Upgrade |
Buy |
Buy |
2023-08-02 |
RBC Capital |
Upgrade |
Outperform |
Outperform |
2023-08-02 |
Morgan Stanley |
Upgrade |
Overweight |
Overweight |
2023-08-02 |
Needham |
Upgrade |
|
Buy |
2023-07-13 |
Morgan Stanley |
Upgrade |
Overweight |
Overweight |
2023-06-22 |
Needham |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-02-29 |
BARRY RICHARD J |
Director |
3.18M |
Stock Award(Grant) |
2024-02-29 |
BEHRENS M KATHLEEN |
Director |
186.84K |
Stock Award(Grant) |
2024-03-10 |
BOOR KATHRYN JEAN |
Director |
7.52K |
Sale |
2024-02-29 |
BROWN RYAN EDWARD |
General Counsel |
31.83K |
Stock Award(Grant) |
2024-02-29 |
ESTEPAN IAN MICHAEL |
Chief Financial Officer |
39.11K |
Stock Award(Grant) |
2024-03-04 |
MAYO STEPHEN L. |
Director |
6.62K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
8.53M |
977.02M |
9.69% |
2023-06-29 |
Blackrock Inc. |
5.50M |
630.26M |
6.25% |
2023-06-29 |
Janus Henderson Group PLC |
5.45M |
623.87M |
6.19% |
2023-06-29 |
Avoro Capital Advisors LLC |
4.63M |
529.99M |
5.26% |
2023-06-29 |
JP Morgan Chase & Company |
4.40M |
504.36M |
5.00% |
2023-06-29 |
Wellington Management Group, LLP |
3.86M |
441.49M |
4.38% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
2.78M |
317.87M |
3.15% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
2.28M |
261.62M |
2.60% |
2023-07-30 |
Vanguard Specialized-Health Care Fund |
2.28M |
247.53M |
2.60% |
2023-06-29 |
JP Morgan Large Cap Growth Fund |
1.46M |
167.08M |
1.66% |
2023-06-29 |
Vanguard Small-Cap Growth Index Fund |
1.31M |
149.65M |
1.48% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.29M |
147.57M |
1.46% |
Split |
Date |
0.16667 : 1 |
2012-07-12 |